![David Alastair Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Alastair Smith
Vorsitzender bei
THERACRYF PLC
Vermögen: 1 Mio $ am 31.07.2026
Profil
David Alastair MacLaughlin Smith was the founder of Avacta Group Plc, founded in 2004, where the title held was Chief Executive Officer & Executive Director from 2005 to 2024.
Current jobs include Non-Executive Chairman at SPARTA Biodiscovery Ltd., Non-Executive Chairman at TheraCryf Plc starting in 2025, and Independent Non-Executive Director at Thalia Therapeutics Plc starting in 2025.
Former jobs include Chief Executive Officer & Director at Avacta Life Sciences Ltd., Director-Institute of Molecular Biophysics at the University of Leeds, and Director at TheraGenetics Ltd. Education includes undergraduate and doctorate degrees from The University of Manchester.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AVACTA GROUP PLC 0,33 % | 04.06.2025 | 1.565.100 ( 0,33 % ) | 1 Mio $ | 31.07.2026 |
THERACRYF PLC 0,19 % | 31.03.2025 | 4.000.000 ( 0,19 % ) | 10 480 $ | 31.07.2026 |
Aktive Positionen von David Alastair Smith
| Unternehmen | Position | Beginn |
|---|---|---|
| THALIA THERAPEUTICS PLC | Direktor/Vorstandsmitglied | 08.01.2025 |
| THERACRYF PLC | Vorsitzender | 19.02.2025 |
Sparta Biodiscovery Ltd.
 Sparta Biodiscovery Ltd. Medical SpecialtiesHealth Technology Manufactures instruments for chemical analysis and pharmaceutical research | Vorsitzender | - |
Ehemalige bekannte Positionen von David Alastair Smith
| Unternehmen | Position | Ende |
|---|---|---|
| AVACTA GROUP PLC | Gründer | 01.05.2024 |
Avacta Life Sciences Ltd.
 Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Vorstandsvorsitzender | - |
TheraGenetics Ltd.
 TheraGenetics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures brachytherapy seeds for prostate and localized cancers | Direktor/Vorstandsmitglied | - |
University of Leeds
 University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Ausbildung von David Alastair Smith
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
49
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Evgen Pharma Plc
 Evgen Pharma Plc Medical/Nursing ServicesHealth Services Engages in the development of pharmaceutical products and focus on cancer & neurological disease | Health Services |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Leeds
University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avacta Group Plc
 Avacta Group Plc Miscellaneous Commercial ServicesCommercial Services Engages in the business of healthcare technology and consumables | Commercial Services |
TheraGenetics Ltd.
TheraGenetics Ltd. Pharmaceuticals: MajorHealth Technology Manufactures brachytherapy seeds for prostate and localized cancers | Health Technology |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
N4 Pharma Plc
 N4 Pharma Plc BiotechnologyHealth Technology Provides specialist pharmaceutical services that reformulates existing drugs and vaccines to improve their performance | Health Technology |
Sparta Biodiscovery Ltd.
Sparta Biodiscovery Ltd. Medical SpecialtiesHealth Technology Manufactures instruments for chemical analysis and pharmaceutical research | Health Technology |
